Bridgewater Associates LP Sells 9,593 Shares of Solventum Co. (NYSE:SOLV)

Bridgewater Associates LP lessened its holdings in Solventum Co. (NYSE:SOLV - Free Report) by 50.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,282 shares of the company's stock after selling 9,593 shares during the period. Bridgewater Associates LP's holdings in Solventum were worth $613,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Ontario Teachers Pension Plan Board raised its position in Solventum by 13.2% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 28,298 shares of the company's stock worth $1,869,000 after purchasing an additional 3,310 shares during the period. Aware Super Pty Ltd as trustee of Aware Super bought a new stake in Solventum during the fourth quarter worth about $718,000. Canada Post Corp Registered Pension Plan bought a new position in Solventum during the 4th quarter valued at approximately $148,000. Independent Franchise Partners LLP increased its holdings in shares of Solventum by 105.0% during the fourth quarter. Independent Franchise Partners LLP now owns 1,603,154 shares of the company's stock valued at $105,904,000 after acquiring an additional 821,272 shares in the last quarter. Finally, Petros Family Wealth LLC purchased a new position in shares of Solventum in the fourth quarter worth $205,000.

Solventum Price Performance

Shares of Solventum stock traded down $1.01 during trading on Friday, hitting $66.52. 171,632 shares of the company's stock traded hands, compared to its average volume of 1,307,964. The company has a market cap of $11.51 billion and a PE ratio of 24.19. The firm's fifty day moving average price is $72.74 and its 200 day moving average price is $71.57. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Bank of America upped their price target on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Wednesday, February 26th. Morgan Stanley boosted their price target on Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 5th. Wells Fargo & Company raised their price objective on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. The Goldman Sachs Group raised their target price on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a report on Monday, March 3rd. Finally, Mizuho boosted their price objective on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, Solventum has an average rating of "Hold" and an average target price of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.